Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 5166 results found since Jan 2013.
Cardiologist Eric Topol on How AI Can Bring Humanity Back to Medicine
In his new book, Deep Medicine, the cardiologist argues that artificial intelligence can bring humanity back to medicine.
You tweet several times a day about the latest medical studies. Do you really read all of those articles?
Every one of the 18,000 tweets come from me. People think I have an army of people to help me–no. I’m an information junkie. Ever since I was a kid I’ve been an incessant reader. I apportion time every day–a couple of hours in the morning and the evening.
What is the biggest problem you see in medicine today?
What’s happened is an erosion of the relationship, due to the...
Source: TIME: Health - March 14, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Artificial Intelligence Life Reinvented medicine Source Type: news
Update on Regulation of Regenerative Medicine in Taiwan
Adv Exp Med Biol. 2023;1430:211-219. doi: 10.1007/978-3-031-34567-8_12.ABSTRACTDue to rapid development of biotechnology in recent years, the field of regenerative medicine has attracted considerable attention. Regenerative medicine-related regulations have been established in several countries to ensure the quality, safety, and efficacy of innovative treatments. Considering the diversity of regenerative medicine, the regulatory framework in Taiwan has been adjusted in response to global trend and local demand. Before 2010, cell and gene therapies were regarded as "new medical practice" under the "Medical Care Act." Along ...
Source: Advances in Experimental Medicine and Biology - August 1, 2023 Category: Research Authors: Wan-Yu Chao Yi-Ting Chang Yueh-Tung Tsai Mei-Chen Huang Yi-Chu Lin Min-Mei Wu Jo-Feng Chi Chien-Liang Lin Hwei-Fang Cheng Shou-Mei Wu Source Type: research
Clinical implications of omics and systems medicine: focus on predictive and individualized treatment
Abstract
Many patients with common diseases do not respond to treatment. This is a key challenge to modern health care, which causes both suffering and enormous costs. One important reason for the lack of treatment response is that common diseases are associated with altered interactions between thousands of genes, in combinations that differ between subgroups of patients who do or do not respond to a given treatment. Such subgroups, or even distinct disease entities, have been described recently in asthma, diabetes, autoimmune diseases and cancer. High‐throughput techniques (omics) allow identification and characterizat...
Source: Journal of Internal Medicine - August 19, 2015 Category: Internal Medicine Authors: M. Benson Tags: Review Source Type: research
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
This article provides an overview of already approved agents as well as those on the horizon. It is important that as these agents are clinically onboarded, nuclear medicine physicians have the expertise to deploy theranostics safely and efficiently, ensuring that these agents attain and maintain their position as leading lines of therapy in managing patients with cancer as well as becoming an important aspect of nuclear medicine practice in the future.
Source: Journal of Nuclear Medicine - March 1, 2020 Category: Nuclear Medicine Authors: Solnes, L. B., Werner, R. A., Jones, K. M., Sadaghiani, M. S., Bailey, C. R., Lapa, C., Pomper, M. G., Rowe, S. P. Tags: The State of the Art Source Type: research
The evolving regulatory landscape in regenerative medicine
Mol Aspects Med. 2022 Aug 29:101138. doi: 10.1016/j.mam.2022.101138. Online ahead of print.ABSTRACTRegenerative medicine as a field has emerged as a new component of modern medicine and medical research that encompasses a wide range of products including cellular and acellular therapies. As this new field emerged, regulatory agencies like the Food and Drug Administration (FDA) rapidly adapted existing regulatory frameworks to address the transplantation, gene therapy, cell-based therapeutics, and acellular biologics that fall under the broader regenerative medicine umbrella. Where it has not been possible to modify existin...
Source: Molecular Medicine - September 1, 2022 Category: Molecular Biology Authors: Danielle J Beetler Damian N Di Florio Ethan W Law Chris M Groen Anthony J Windebank Quinn P Peterson DeLisa Fairweather Source Type: research
Red Blood Cell Omics and Machine Learning in Transfusion Medicine: Singularity Is Near
Background: Blood transfusion is a life-saving intervention for millions of recipients worldwide. Over the last 15 years, the advent of high-throughput, affordable omics technologies – including genomics, proteomics, lipidomics, and metabolomics – has allowed transfusion medicine to revisit the biology of blood donors, stored blood products, and transfusion recipients.Summary: Omics approaches have shed light on the genetic and non-genetic factors (environmental or other exposures) impacting the quality of stored blood products and efficacy of transfusion events, based on the current Food and Drug Administration guidel...
Source: Transfusion Medicine and Hemotherapy - March 8, 2023 Category: Hematology Source Type: research
Expert consensus for postmarketing Chinese medicine intensive hospital safety monitoring
It is of vital significance to conduct active postmarketing surveillance of Chinese medicine, as an active response to laws, rules and guidelines issued by the China Food and Drug Administration. These will provide technological support in evaluating adverse drug reactions (ADRs) or adverse drug events (ADEs). The consensus has been developed by drawing on postmarketing safety monitoring of medicines and the advanced design concepts and methodologies from home and abroad, and complying with national laws, regulations and technical guidance documents, whilst taking into consideration the characteristics of CMs and the actua...
Source: European Journal of Integrative Medicine - November 13, 2014 Category: Complementary Medicine Authors: Yan-ming Xie, Xing Liao, Wen Zhang, Feng Tian, Yu-bin Zhao, Ming-quan Li, Yun-ling Zhang, Rong Ma, Shao-xiang Xian, Jian Liu, Su-yun Li, Ze-huai Wen, Zhong-qi Yang, Jian-dong Zou, Hong-sheng Sun, Yan He, Xue-lin Li, Jun-jie Jiang, Zhi-fei Wang, Yuan-yuan Tags: Abstracts GPTCM –RA and Speciality Committee of TCM Pharmaceutical analysis of WFCMS Source Type: research
Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement
The diagnosis and effective treatment of obstructive sleep apnea (OSA) in adults is an urgent health priority. Positive airway pressure (PAP) therapy remains the most effective treatment for OSA, although other treatment options continue to be explored. Limited evidence citing small pilot or proof of concept studies suggest that the synthetic medical cannabis extract dronabinol may improve respiratory stability and provide benefit to treat OSA. However, side effects such as somnolence related to treatment were reported in most patients, and the long-term effects on other sleep quality measures, tolerability, and safety are...
Source: Journal of Clinical Sleep Medicine : JCSM - April 13, 2018 Category: Sleep Medicine Source Type: research
Consumer Sleep Technology: An American Academy of Sleep Medicine Position Statement
Consumer sleep technologies (CSTs) are widespread applications and devices that purport to measure and even improve sleep. Sleep clinicians may frequently encounter CST in practice and, despite lack of validation against gold standard polysomnography, familiarity with these devices has become a patient expectation. This American Academy of Sleep Medicine position statement details the disadvantages and potential benefits of CSTs and provides guidance when approaching patient-generated health data from CSTs in a clinical setting. Given the lack of validation and United States Food and Drug Administration (FDA) clearance, CS...
Source: Journal of Clinical Sleep Medicine : JCSM - May 15, 2018 Category: Sleep Medicine Source Type: research
National Academy of Medicine and FDA announce Tobacco Regulatory Science Fellows
(National Academy of Sciences) The National Academy of Medicine, formerly the Institute of Medicine, along with the Food and Drug Administration's Center for Tobacco Products have named the 2015-2016 class of the FDA Tobacco Regulatory Science Fellows.
Source: EurekAlert! - Medicine and Health - August 3, 2015 Category: Global & Universal Source Type: news
